Literature DB >> 18520984

Aripiprazole and haloperidol: beneficial combination antipsychotic therapy for a schizophrenic patient.

Joseph Kuo1, Hai-Gwo Hwu.   

Abstract

OBJECTIVE: Schizophrenia is a chronic disease that is treated with dopamine antagonists. These drugs can produce intolerable side effects through their blockade of central nervous system dopamine receptors unrelated to schizophrenia. The atypical antipsychotic aripiprazole, a dopamine receptor partial agonist, has mixed agonist-antagonist effects. Its partial agonism is said to protect the patient from the side effects caused by full antagonists at the same time that its antagonism treats the schizophrenia effectively. CASE: We report a case in which a low dose of the full antagonist haloperidol, added to aripiprazole, improved antipsychotic efficacy in a 41-year-old man diagnosed with undifferentiated schizophrenia. RESULT: A 15-mg/d aripiprazole/7.5-mg/d haloperidol regime in this patient improved all previous psychotic symptoms and caused no adverse side effects. The patient's final prolactin concentration using this combination was normal.
CONCLUSION: Further studies are warranted to confirm this observation and to determine the mechanism through which a carefully titrated combination of a full antagonist with a partial agonist can cause such improvement.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18520984     DOI: 10.1097/WNF.0b013e318123ee01

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  2 in total

1.  Aripiprazole use combined with depot antipsychotic medication: two cases demonstrating its ability to reduce prolactin levels in an adolescent forensic hospital.

Authors:  Simon A Hill; Al Aditya Khan; Marion Wetherill
Journal:  Ther Adv Psychopharmacol       Date:  2011-06

2.  Identification of Novel Dopamine D2 Receptor Ligands-A Combined In Silico/In Vitro Approach.

Authors:  Lukas Zell; Constanze Lainer; Jakub Kollár; Veronika Temml; Daniela Schuster
Journal:  Molecules       Date:  2022-07-11       Impact factor: 4.927

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.